Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;43(3):921-927.
doi: 10.1007/s10067-024-06869-9. Epub 2024 Jan 25.

Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups

Affiliations

Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups

Jacqueline O'Brien et al. Clin Rheumatol. 2024 Mar.

Abstract

To examine racial/ethnic differences in rheumatoid arthritis (RA) disease burden and change in clinical outcomes over time. We included CorEvitas Rheumatoid Arthritis Registry patients from two time periods (2013-2015 and 2018-2020). Clinical Disease Activity Index (CDAI) (as a continuous measure and as a dichotomous measure) and the Health Assessment Questionnaire-Disability Index (HAQ-DI) were assessed at each visit. Marginal means and their corresponding 95% confidence interval (CI) by race/ethnicity were estimated for each outcome using adjusted mixed effects linear and logistic regression models. Overall and pairwise tests were conducted to detect differences between race/ethnicity groups. Of 9,363 eligible patients (8,142 White, 527 Black, 545 Hispanic, 149 Asian), most (76%-85%) were female. At Visit 1, the mean disease duration ranged from 9.8-11.8 years. Estimated CDAI was significantly higher for Hispanics compared to Whites at Visit 1 (11.1 vs. 9.9; pairwise P = 0.033) and Visit 2 (9.2 vs. 8.0, pairwise P = 0.005). Disease activity improved over the 5-year study period among all race/ethnicity groups, though Hispanics improved less than Whites. Disease activity improved over the 5-year period across all racial/ethnicity groups, and disparities between racial/ethnicity groups in disease activity and functional status did persist over time, suggesting that further effort is needed to understand the drivers of these discrepancies to close this race/ethnicity gap. Key Points • Disease activity improved over the 5-year period across all racial and ethnic groups. • Disparities between racial and ethnic groups in disease activity and functional status did persist over time, suggesting that further effort is needed to understand the drivers of these discrepancies and close this racial gap.

Keywords: Disease burden; Health disparities; Longitudinal analysis; Race and ethnicity; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

JO, TB, MM, NM are employees of CorEvitas, LLC; SHP, KW are employees/stockholders of Bristol Myers Squibb; LRH is an employee and shareholder of CorEvitas, LLC, who is on the speaker’s bureau for Bristol Myers Squibb, and has received consulting fees from AbbVie, Bristol Myers Squibb and Roche and grant funding from Pfizer.

Figures

Fig. 1
Fig. 1
Adjusted marginal mean change in CDAI and HAQ-DI from Visit 1 to Visit 2, and adjusted probabilities of achievement of LDA and remission at Visit 2 by race/ethnicity. See Online Resource for details on variables included in each final model

Similar articles

Cited by

References

    1. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi: 10.1038/nrdp.2018.1. - DOI - PubMed
    1. Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. doi: 10.1007/s00296-020-04731-0. - DOI - PubMed
    1. Ramiro S, Landewé RB, van der Heijde D, et al. Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM) Ann Rheum Dis. 2020;79:453–459. doi: 10.1136/annrheumdis-2019-216819. - DOI - PubMed
    1. Xu Y, Wu Q. Prevalence trend and disparities in rheumatoid arthritis among US adults, 2005–2018. J Clin Med. 2021;10(15):3289. doi: 10.3390/jcm10153289. - DOI - PMC - PubMed
    1. Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013;65(2):299–303. doi: 10.1002/acr.21798. - DOI - PubMed

MeSH terms